Dr. Patrick R. Oellers, MD
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 1,161
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
NY license 293024
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University Hospital S U N Y Health Science Center Syracuse, NY
- Crouse Hospital Syracuse, NY
Medical groups
- Ophthalmology Medical Service Group Inc (30 clinicians)
- Retina-Vitreous Surgeons of Central New York PC (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,161
- Services billed
- 46,916
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 7,860 | 16 |
| Injection, aflibercept, 1 mg | 3,506 | 308 |
| Imaging of retina | 3,339 | 1,025 |
| Injection of drug into eye | 1,958 | 385 |
| Injection, ranibizumab, 0.1 mg | 1,474 | 58 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 570 | 20 |
| Established patient complete exam of visual system | 524 | 426 |
| Established patient office or other outpatient visit, 30-39 minutes | 516 | 386 |
| Established patient office or other outpatient visit, 20-29 minutes | 290 | 202 |
| New patient complete exam of visual system | 135 | 135 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Liverpool, NY | 283 |
| Tobramycin | 129 |
| Ketorolac Tromethamine Other prescribers in Liverpool, NY | 121 |
| Dorzolamide Hcl Other prescribers in Liverpool, NY | 51 |
| Timolol Maleate Other prescribers in Liverpool, NY | 51 |
| Brimonidine Tartrate Other prescribers in Liverpool, NY | 49 |
| Erythromycin (erythromycin base) Other prescribers in Liverpool, NY | 26 |
| Latanoprost Other prescribers in Liverpool, NY | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $4,474 in total to this clinician.
| Astellas Pharma Global Development | $4,400 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $39.33 |
| Ocular Therapeutix, Inc. | $19.54 |
| Sandoz Inc. | $15.34 |
| Consulting Fee | $4,400 |
|---|---|
| Food and Beverage | $74.21 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma Global Development Apr 3, 2025 | Consulting Fee Izervay · Ophthalmology | $4,400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $272,441 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. - A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular…
Astellas Pharma Global Development - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion
Regeneron Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.